Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | GRM8 | O00222 | 1/20 | 0.33 |
| ▸ | GRM6 | O15303 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1841835 | 1.00 | LTA4H (0.43) | LTA4HNOS1NOS3NOS2SLC1A1 | |
| SCHEMBL18477 | 1.00 | LTA4H (0.43) | LTA4HNOS1NOS3NOS2SLC1A1 | |
| Hydrochloric Acid SCHEMBL4654220 | 0.98 | LTA4H (0.42) | LTA4HNOS1NOS3NOS2SLC1A1 | |
| SCHEMBL6893763 | 0.98 | LTA4H (0.42) | LTA4HNOS1NOS3NOS2SLC1A1 | |
| Hydrochloric Acid SCHEMBL18476 | 0.98 | LTA4H (0.42) | LTA4HNOS1NOS3NOS2SLC1A1 | |
| Water SCHEMBL27596082 | 0.98 | LTA4H (0.42) | LTA4HNOS1NOS3NOS2SLC1A1 | |
| Water SCHEMBL3912787 | 0.98 | LTA4H (0.42) | LTA4HNOS1NOS3NOS2SLC1A1 | |
| Hydrochloric Acid SCHEMBL1517836 | 0.98 | LTA4H (0.42) | LTA4HNOS1NOS3NOS2SLC1A1 | |
| SCHEMBL18744647 | 0.90 | LTA4H (0.40) | LTA4HNOS1NOS3NOS2SLC1A1 | |
| SCHEMBL23416460 | 0.89 | LTA4H (0.39) | LTA4HNOS1NOS3NOS2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110272468-B | Preparation and application of prostate specific membrane antigen small molecule inhibitor and radionuclide complex thereof | 上海益泰医药科技有限公司 | 2020-12-08 | — | — | CN | claimed |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCE INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250269043-A1 | TARGETED BIFUNCTIONAL DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-08-28 | — | — | US | disclosed |
| CN-119562958-A | Methods for preparing NAG-25 carbohydrate targeting moieties and intermediates thereof | 安进公司 | 2025-03-04 | — | — | CN | disclosed |
| EP-4493221-A2 | TARGETED BIFUNCTIONAL DEGRADERS | Yale University (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-119212727-A | Targeted bifunctional degradants | 耶鲁大学 | 2024-12-27 | — | — | CN | disclosed |
| WO-2024224093-A1 | DESMURAMYLPEPTIDE DIEESTERS AS NOD2 AGONISTS AND USE THEREOF | Imhotex Limited (GB) | 2024-10-31 | — | — | WO | disclosed |
| EP-4440701-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2024-10-09 | — | — | EP | disclosed |
| WO-2024105205-A1 | ANTIBODY-DRUG CONJUGATES (A2DCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-23 | — | — | WO | disclosed |
| US-20100068769-A1 | L-GLUTAMIC ACID-PRODUCING MICROORGANISM AND A METHOD FOR PRODUCING L-GLUTAMIC ACID | NAKAMURA JUN | 2010-03-18 | — | — | US | disclosed |
| EP-1831250-A2 | L-GLUTAMIC ACID-PRODUCING MICROORGANISM AND A METHOD FOR PRODUCING L-GLUTAMIC ACID | Ajinomoto Co., Inc. (JP) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006070944-A2 | L-GLUTAMIC ACID-PRODUCING MICROORGANISM AND A METHOD FOR PRODUCING L-GLUTAMIC ACID | AJINOMOTO CO., INC. (JP) | 2006-07-06 | — | — | WO | disclosed |
| US-20060141588-A1 | L-GLUTAMIC ACID-PRODUCING MICROORGANISM AND A METHOD FOR PRODUCING L-GLUTAMIC ACID | AJINOMOTO CO., INC. (JP) | 2006-06-29 | — | — | US | disclosed |
| US-5187167-A | Antitumor agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-02-16 | — | — | US | disclosed |
| US-5108990-A | GLUTAMIC ACID DERIVATIVES | ROUSSEL UCLAF (FR) | 1992-04-28 | — | — | US | disclosed |
| US-5081124-A | Amino acid and polyamino acid derivatives, inhibitors of thymidylate synthetase | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-01-14 | — | — | US | disclosed |
| US-4992550-A | Thymidylate synthetase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-02-12 | — | — | US | disclosed |
| US-4956461-A | LEUKEMIA, ANTICARCINOGENIC AGENTS | DANA FARBER CANCER INSTITUTE, INC. (US) | 1990-09-11 | — | — | US | disclosed |
| WO-1990004593-A1 | DESAMINO-AMINOPTERIN AND -METHOTREXATE | DANA-FARBER CANCER INSTITUTE (US) | 1990-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250269043-A1 | TARGETED BIFUNCTIONAL DEGRADERS | SMURF2, SMURF1, MDM2 | LTA4H 3924/4885NOS1 3482/4885NOS3 4005/4885 |
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | LTA4H 1204/4885NOS1 2449/4885NOS3 1219/4885 |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | CCR10, CCR1, CCR3 | LTA4H 3109/4885NOS1 1238/4885NOS3 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.